# TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)

Study · id `cardio:ct-nct01090037` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01090037](<https://clinicaltrials.gov/study/NCT01090037>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01090037

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 892 participants.

## Technical summary

Registry record NCT01090037. Randomized; double masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2014-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 892 participants (enrolled count; ClinicalTrials.gov record NCT01090037, source copy `cardio:ctgov-nct01090037-2015-02-04`, retrieved 2026-10-26)
- Start date: 2010-03 (registry gives no type) (ClinicalTrials.gov record NCT01090037, source copy `cardio:ctgov-nct01090037-2015-02-04`, retrieved 2026-10-26)
- Primary completion: 2014-08 (actual) (ClinicalTrials.gov record NCT01090037, source copy `cardio:ctgov-nct01090037-2015-02-04`, retrieved 2026-10-26)
- Completion: 2015-01 (actual) (ClinicalTrials.gov record NCT01090037, source copy `cardio:ctgov-nct01090037-2015-02-04`, retrieved 2026-10-26)
- Countries: China; Hong Kong SAR China; Japan; Malaysia; South Korea; Taiwan; Thailand (ClinicalTrials.gov record NCT01090037, source copy `cardio:ctgov-nct01090037-2015-02-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01090037-2015-02-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)
- Condition: Chronic Renal Failure
- Condition: Glomerular Disease
- Condition: Nephrosclerosis
- Intervention (Drug): TRK-100STP high dose
- Intervention (Drug): TRK-100STP low dose
- Intervention (Drug): Placebo
- Lead sponsor: Toray Industries, Inc
- Lead sponsor class: INDUSTRY
- Collaborator: Astellas Pharma Inc
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as a collaborator: Astellas Pharma Inc (`cardio:org-astellas-pharma-inc`)

## Provenance

Content hash: 60fd20a817b94b3a8f2ba808bb2a22d6999548372ccdd9378e17fd3e4130acd1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
